Clinical and molecular implications of MED15 in head and neck squamous cell carcinoma

David Adler1, Anne Offermann1, Rebecca Halbach1

  • 1Department of Prostate Cancer Research, University Hospital of Bonn, Bonn, Germany; Institute of Pathology, University Hospital of Bonn, Bonn, Germany.

Insights

Mediator subunit MED15 is overexpressed in head and neck squamous cell carcinoma (HNSCC), correlating with recurrence and mortality. MED15 may be a prognostic marker and therapeutic target for HNSCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Head and neck squamous cell carcinoma (HNSCC) progression involves dysregulated pathways.
  • The mediator complex regulates diverse pathways, with MED15 being crucial for transforming growth factor (TGF)-β signaling.
  • MED15's role in breast and prostate cancers suggests its potential involvement in HNSCC.

Purpose of the Study:

  • To investigate the implication and role of MED15 in head and neck squamous cell carcinoma (HNSCC).
  • To assess MED15 as a potential prognostic marker and therapeutic target in HNSCC.

Main Methods:

  • Immunohistochemistry (IHC) for MED15 on 324 HNSCC tissue samples.
  • Assessment of TGF-β signaling using Ki-67 and pSMAD3 markers.
  • MED15 knockdown experiments to evaluate proliferation and migration.
  • Analysis of MED15 expression following TGF-β1 treatment.

Main Results:

  • MED15 was overexpressed in 35% of primary tumors, 30% of lymph node metastases, and 70% of recurrences.
  • MED15 overexpression in primary tumors correlated with higher mortality rates and was frequent in oral/oropharyngeal tumors.
  • MED15 knockdown reduced HNSCC cell proliferation and migration; TGF-β activation increased MED15 expression.

Conclusions:

  • MED15 overexpression is implicated in HNSCC progression and may be a clonal event.
  • MED15 correlates with proliferation and TGF-β signaling activity in HNSCC.
  • MED15 shows potential as a prognostic marker for HNSCC recurrence and a therapeutic target.